|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||58.89 - 59.64|
|52 Week Range||40.02 - 69.07|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||47.22|
|Forward Dividend & Yield||0.14 (0.24%)|
|Ex-Dividend Date||May 01, 2020|
|1y Target Est||N/A|
Spanish pharmaceuticals company Rovi announced on Monday that it will start making the active ingredients for Moderna's COVID-19 vaccine. Rovi will have capacity to supply the active agents for up to 100 million vaccine doses a year at its plant in Granada via a new production line. This would be the first European drug ingredients production site for Moderna outside of Switzerland, where Lonza has one large commercial production line now manufacturing drug substances and another two commercial lines nearing completion.
Swiss contract drug manufacturer Lonza received a key licence from Switzerland to produce ingredients for Moderna's COVID-19 vaccine, regulator Swissmedic said on Monday, a boost for a global inoculation program that has hit some snags. The licence, for Lonza's new $70 million production line in Visp, Switzerland, dedicated to make ingredients for the Moderna vaccine, will help boost the U.S.-based company's deliveries to Europe, Canada and other nations outside the United States.
Altimmune Inc (NASDAQ: ALT) has expanded its previously-announced manufacturing collaboration with Lonza Group (OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate. Under the expansion, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, at its facility near Houston, Texas. In December, the FDA issued a clinical hold on Altimmune's investigational New Drug application for AdCOVID. The agency requested certain protocol modifications and the submission of additional chemistry, manufacturing, and controls data. The recently commenced Phase 1 study with data readout is expected in the second quarter of 2021. Price Action: ALT shares gained 19.7% at $20.20 in the premarket trading on the last check Friday. See more from BenzingaClick here for options trades from BenzingaSanofi, Translate Bio Initiate Human Trial Of mRNA COVID-19 Vaccine CandidatePfizer To Contemplate Additional Production Sites After Pandemic-Related Pressure Is Over: Reuters© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.